Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 8/20 | 0.60 |
| ▸ | PDE4A | P27815 | 6/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693277 | 0.78 | TNF (0.77) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6371914 | 0.78 | TNF (0.44) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7748783 | 0.78 | TNF (0.62) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6693845 | 0.77 | TNF (0.79) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6688763 | 0.76 | TNF (1.00) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4920643 | 0.76 | MAPT (0.61) | MAPTKMT2ATP53 | |
| SCHEMBL4850938 | 0.76 | MAPT (0.59) | MAPTKMT2ATP53 | |
| SCHEMBL1194027 | 0.76 | TNF (0.83) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL825522 | 0.74 | PDE4A (0.82) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28722625 | 0.73 | TNF (0.72) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049371-A1 | Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids | CALGENE CORPORATION | 2001-12-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049371-A1 | Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids | PDE3A, PDE2A, PDE3B | TNF 8/4885PDE4A 6/4885PDE4B 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.